Evidence map›Paper›PMID 21766904›Full record

SynthesisMolecular diagnosis & therapy2011

Serum tests for colorectal cancer screening.

James Creeden, Frank Junker, Sabine Vogel-Ziebolz, Douglas Rex

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Molecular diagnosis & therapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Focus on genetic and epigenetic events of colorectal cancer pathogenesis: implications for molecular diagnosis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

James CreedenRoche Diagnostics, Ltd, Rotkreuz, Switzerland.
Frank Junker
Sabine Vogel-Ziebolz
Douglas Rex

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) persists as one of the most significant causes of cancer death worldwide. Recent progress in reducing cancer mortality can largely be attributed to the implementation of screening programs. However, screening programs have not realized their full potential for the reduction of CRC mortality, because of poor adherence rates among patients. Serum biomarker screening tests offer the potential for improved patient adherence to CRC screening programs. In this review, we assess the literature regarding serum biomarkers for use as CRC screening tests for colorectal cancer and adenomas. A systematic review was performed of Medline-indexed articles pertaining to serum biomarkers for CRC screening published within the past 4 years. In addition, we searched non-Medline sources for information pertaining to screening guidelines and practice patterns for CRC. We identified 51 articles from Medline pertaining to serum biomarkers as screening tests for CRC. Non-Medline sources yielded an additional 12 articles, for a total of 63 publications reviewed. We conclude that serum tests that involve simple blood draws during routine check-ups hold significant promise for improving patient acceptance and adherence to CRC screening.

Indexed as

Biomarkers, TumorColorectal NeoplasmsEarly Detection of CancerHumansBiomarkers, Tumor

Identifiers

PMID21766904

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.